Beyond the inhaled nitric oxide in persistent pulmonary hypertension of the newborn

Mei Yin Lai, Shih Ming Chu, Satyanarayana Lakshminrusimha, Hung Chih Lin

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Persistent pulmonary hypertension (PPHN) is a consequence of failed pulmonary vascular transition at birth and leads to pulmonary hypertension with shunting of deoxygenated blood across the ductus arteriosus (DA) and foramen ovale (FO) resulting in severe hypoxemia, and it may eventually lead to life-threatening circulatory failure. PPHN is a serious event affecting both term and preterm infants in the neonatal intensive care unit. It is often associated with diseases such as congenital diaphragmatic hernia, meconium aspiration, sepsis, congenital pneumonia, birth asphyxia and respiratory distress syndrome. The diagnosis of PPHN should include echocardiographic evidence of increased pulmonary pressure, with demonstrable right-to-left shunt across the DA or FO, and the absence of cyanotic heart diseases. The mainstay therapy of PPHN includes treatment of underlying causes, maintenance of adequate systemic blood pressure, optimized ventilator support for lung recruitment and alveolar ventilation, and pharmacologic measures to increase pulmonary vasodilation and decrease pulmonary vascular resistance. Inhaled nitric oxide has been proved to treat PPHN successfully with improved oxygenation in 60–70% of patients and to significantly reduce the need for extracorporeal membrane oxygenation (ECMO). About 14%–46% of the survivors develop long-term impairments such as hearing deficits, chronic lung disease, cerebral palsy and other neurodevelopmental disabilities.

Original languageEnglish (US)
Pages (from-to)15-23
Number of pages9
JournalPediatrics and Neonatology
Volume59
Issue number1
DOIs
StatePublished - Feb 1 2018
Externally publishedYes

Fingerprint

Persistent Fetal Circulation Syndrome
Pulmonary Hypertension
Nitric Oxide
Foramen Ovale
Ductus Arteriosus
Lung
Parturition
Meconium Aspiration Syndrome
Extracorporeal Membrane Oxygenation
Asphyxia
Neonatal Intensive Care Units
Cerebral Palsy
Mechanical Ventilators
Premature Infants
Vasodilation
Vascular Resistance
Lung Diseases
Hearing
Blood Vessels
Ventilation

Keywords

  • newborn
  • nitric oxide
  • persistent pulmonary hypertension of newborn
  • pulmonary hypertension

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Beyond the inhaled nitric oxide in persistent pulmonary hypertension of the newborn. / Lai, Mei Yin; Chu, Shih Ming; Lakshminrusimha, Satyanarayana; Lin, Hung Chih.

In: Pediatrics and Neonatology, Vol. 59, No. 1, 01.02.2018, p. 15-23.

Research output: Contribution to journalReview article

@article{39393452e08343a78ffd30851d16d911,
title = "Beyond the inhaled nitric oxide in persistent pulmonary hypertension of the newborn",
abstract = "Persistent pulmonary hypertension (PPHN) is a consequence of failed pulmonary vascular transition at birth and leads to pulmonary hypertension with shunting of deoxygenated blood across the ductus arteriosus (DA) and foramen ovale (FO) resulting in severe hypoxemia, and it may eventually lead to life-threatening circulatory failure. PPHN is a serious event affecting both term and preterm infants in the neonatal intensive care unit. It is often associated with diseases such as congenital diaphragmatic hernia, meconium aspiration, sepsis, congenital pneumonia, birth asphyxia and respiratory distress syndrome. The diagnosis of PPHN should include echocardiographic evidence of increased pulmonary pressure, with demonstrable right-to-left shunt across the DA or FO, and the absence of cyanotic heart diseases. The mainstay therapy of PPHN includes treatment of underlying causes, maintenance of adequate systemic blood pressure, optimized ventilator support for lung recruitment and alveolar ventilation, and pharmacologic measures to increase pulmonary vasodilation and decrease pulmonary vascular resistance. Inhaled nitric oxide has been proved to treat PPHN successfully with improved oxygenation in 60–70{\%} of patients and to significantly reduce the need for extracorporeal membrane oxygenation (ECMO). About 14{\%}–46{\%} of the survivors develop long-term impairments such as hearing deficits, chronic lung disease, cerebral palsy and other neurodevelopmental disabilities.",
keywords = "newborn, nitric oxide, persistent pulmonary hypertension of newborn, pulmonary hypertension",
author = "Lai, {Mei Yin} and Chu, {Shih Ming} and Satyanarayana Lakshminrusimha and Lin, {Hung Chih}",
year = "2018",
month = "2",
day = "1",
doi = "10.1016/j.pedneo.2016.09.011",
language = "English (US)",
volume = "59",
pages = "15--23",
journal = "Pediatrics and Neonatology",
issn = "1875-9572",
publisher = "Elsevier (Singapore) Pte Ltd",
number = "1",

}

TY - JOUR

T1 - Beyond the inhaled nitric oxide in persistent pulmonary hypertension of the newborn

AU - Lai, Mei Yin

AU - Chu, Shih Ming

AU - Lakshminrusimha, Satyanarayana

AU - Lin, Hung Chih

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Persistent pulmonary hypertension (PPHN) is a consequence of failed pulmonary vascular transition at birth and leads to pulmonary hypertension with shunting of deoxygenated blood across the ductus arteriosus (DA) and foramen ovale (FO) resulting in severe hypoxemia, and it may eventually lead to life-threatening circulatory failure. PPHN is a serious event affecting both term and preterm infants in the neonatal intensive care unit. It is often associated with diseases such as congenital diaphragmatic hernia, meconium aspiration, sepsis, congenital pneumonia, birth asphyxia and respiratory distress syndrome. The diagnosis of PPHN should include echocardiographic evidence of increased pulmonary pressure, with demonstrable right-to-left shunt across the DA or FO, and the absence of cyanotic heart diseases. The mainstay therapy of PPHN includes treatment of underlying causes, maintenance of adequate systemic blood pressure, optimized ventilator support for lung recruitment and alveolar ventilation, and pharmacologic measures to increase pulmonary vasodilation and decrease pulmonary vascular resistance. Inhaled nitric oxide has been proved to treat PPHN successfully with improved oxygenation in 60–70% of patients and to significantly reduce the need for extracorporeal membrane oxygenation (ECMO). About 14%–46% of the survivors develop long-term impairments such as hearing deficits, chronic lung disease, cerebral palsy and other neurodevelopmental disabilities.

AB - Persistent pulmonary hypertension (PPHN) is a consequence of failed pulmonary vascular transition at birth and leads to pulmonary hypertension with shunting of deoxygenated blood across the ductus arteriosus (DA) and foramen ovale (FO) resulting in severe hypoxemia, and it may eventually lead to life-threatening circulatory failure. PPHN is a serious event affecting both term and preterm infants in the neonatal intensive care unit. It is often associated with diseases such as congenital diaphragmatic hernia, meconium aspiration, sepsis, congenital pneumonia, birth asphyxia and respiratory distress syndrome. The diagnosis of PPHN should include echocardiographic evidence of increased pulmonary pressure, with demonstrable right-to-left shunt across the DA or FO, and the absence of cyanotic heart diseases. The mainstay therapy of PPHN includes treatment of underlying causes, maintenance of adequate systemic blood pressure, optimized ventilator support for lung recruitment and alveolar ventilation, and pharmacologic measures to increase pulmonary vasodilation and decrease pulmonary vascular resistance. Inhaled nitric oxide has been proved to treat PPHN successfully with improved oxygenation in 60–70% of patients and to significantly reduce the need for extracorporeal membrane oxygenation (ECMO). About 14%–46% of the survivors develop long-term impairments such as hearing deficits, chronic lung disease, cerebral palsy and other neurodevelopmental disabilities.

KW - newborn

KW - nitric oxide

KW - persistent pulmonary hypertension of newborn

KW - pulmonary hypertension

UR - http://www.scopus.com/inward/record.url?scp=85028940730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028940730&partnerID=8YFLogxK

U2 - 10.1016/j.pedneo.2016.09.011

DO - 10.1016/j.pedneo.2016.09.011

M3 - Review article

C2 - 28923474

AN - SCOPUS:85028940730

VL - 59

SP - 15

EP - 23

JO - Pediatrics and Neonatology

JF - Pediatrics and Neonatology

SN - 1875-9572

IS - 1

ER -